Stephens Investment Management Group LLC Acquires 281,327 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Stephens Investment Management Group LLC grew its stake in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 22.1% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,555,809 shares of the medical device company's stock after buying an additional 281,327 shares during the period. Stephens Investment Management Group LLC owned 2.37% of Tandem Diabetes Care worth $56,040,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of TNDM. Bellevue Group AG grew its position in shares of Tandem Diabetes Care by 19.9% in the third quarter. Bellevue Group AG now owns 1,850,891 shares of the medical device company's stock valued at $78,496,000 after purchasing an additional 307,624 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Tandem Diabetes Care by 397.3% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 301,614 shares of the medical device company's stock valued at $11,121,000 after purchasing an additional 240,966 shares during the period. Point72 Asset Management L.P. purchased a new stake in shares of Tandem Diabetes Care in the third quarter valued at $10,208,000. Victory Capital Management Inc. grew its position in shares of Tandem Diabetes Care by 45.6% in the third quarter. Victory Capital Management Inc. now owns 587,247 shares of the medical device company's stock valued at $24,905,000 after purchasing an additional 183,877 shares during the period. Finally, Chicago Capital LLC grew its position in shares of Tandem Diabetes Care by 22.2% in the third quarter. Chicago Capital LLC now owns 1,003,147 shares of the medical device company's stock valued at $42,543,000 after purchasing an additional 182,085 shares during the period.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. Morgan Stanley upgraded Tandem Diabetes Care from an "equal weight" rating to an "overweight" rating and set a $45.00 target price on the stock in a report on Monday, December 2nd. Citigroup reduced their target price on Tandem Diabetes Care from $57.00 to $50.00 and set a "buy" rating on the stock in a report on Wednesday, December 11th. Robert W. Baird reduced their target price on Tandem Diabetes Care from $39.00 to $37.00 and set a "neutral" rating on the stock in a report on Thursday, November 7th. Canaccord Genuity Group reduced their target price on Tandem Diabetes Care from $57.00 to $56.00 and set a "buy" rating on the stock in a report on Thursday, November 7th. Finally, Sanford C. Bernstein assumed coverage on Tandem Diabetes Care in a report on Wednesday, November 6th. They issued an "outperform" rating and a $42.00 target price on the stock. Four investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $53.81.

Insider Transactions at Tandem Diabetes Care

In other Tandem Diabetes Care news, Director Kim D. Blickenstaff sold 10,000 shares of Tandem Diabetes Care stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $30.00, for a total value of $300,000.00. Following the sale, the director now directly owns 195,190 shares in the company, valued at approximately $5,855,700. The trade was a 4.87 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 2.20% of the company's stock.

Tandem Diabetes Care Price Performance

Shares of Tandem Diabetes Care stock traded down $0.61 during midday trading on Wednesday, reaching $32.91. The company had a trading volume of 710,930 shares, compared to its average volume of 908,205. The company has a current ratio of 2.90, a quick ratio of 2.32 and a debt-to-equity ratio of 1.29. The company has a market capitalization of $2.16 billion, a price-to-earnings ratio of -17.05 and a beta of 1.32. The stock has a fifty day simple moving average of $35.49 and a 200 day simple moving average of $37.01. Tandem Diabetes Care, Inc. has a 1-year low of $22.03 and a 1-year high of $53.69.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.